153710 fundamentals

Optipharm Co., Ltd. engages in the business of animal disease diagnosis and pharmaceuticals. It operates through the following business divisions: Xenograft, VLP Vaccine, Bacteriophage, Animal Disease Unit, and Human Diagnostic Kit. The Xenograft business division includes Medipig. The VPL Vaccine business division is involved in research and development of vaccine products. The Bacteriophage business division focuses on developing bacteriophages that have the characteristic of eliminating bacteria without affecting animal cells and beneficial bacteria. The Animal Disease Unit business division refers to detecting and diagnosing porcine cytomegalovirus and its kit. The Human Diagnostic Kit business division refers to diagnostic method and kit for simultaneous detection and identification of mycobacterium tuberculosis and nontuberculous mycobacteria. The company was founded on July 27, 2000 and is headquartered in Cheongju-si, South Korea.